Recommended Free Tools
Achieve Life Sciences announced on October 1, 2026, that Benjamin Halladay, CPA, will become its chief financial officer on October 5. He succeeds Mark Oki, who is stepping down from the role that day. Achieve says the appointment strengthens its finance leadership as it prepares for the possible commercialization of cytisinicline, a drug candidate that remains under development and has not been established as approved or available.
When Halladay becomes CFO and what his role covers
Halladay’s appointment takes effect October 5, 2026, according to Achieve Life Sciences’ October 1 announcement. The company says he will oversee financial strategy, accounting, investor relations, information technology and other administrative functions. Mark Oki leaves the CFO role on the same date; the announcement does not provide further details about his departure.
Who Benjamin Halladay is
Achieve describes Halladay as a finance executive with more than 15 years of financial management experience and public-company CFO experience in commercial pharmaceuticals and business development. The company says he was CFO of Esperion Therapeutics from November 2022 through July 2026.
In its announcement, Achieve credits Halladay with helping Esperion deleverage its balance sheet, acquire Corstasis Therapeutics and its product Enbumyst, and lead the finance workstream through Esperion’s sale to ARCHIMED. Achieve also says Esperion generated more than $400 million in annual revenue and that the sale had a stated maximum value of up to $1.1 billion. Those figures and descriptions are Achieve’s account of Halladay’s tenure and the transaction.
Free tools Windows power users keep installed
One-click scans. No signup required.
#1 Best Overall
Achieve says the sale’s upfront cash consideration represented a 58% premium to Esperion’s closing share price on April 30, 2026. That percentage refers to the premium against that specific share price, not a general measure of the sale’s value.
Earlier in his career, Halladay held positions at Pfizer, including work on Lipitor and Chantix in its Primary Care business unit, and at National Oilwell Varco, according to Achieve. The company says he earned an MBA from Fordham University and a BA from Syracuse University, and is an inactive Certified Public Accountant.
Rank #2
- Ideal for Gifting
- Ideal for a bookworm
- Compact for travelling
Why Achieve says it made the appointment
Achieve links the hire to its preparations for potential commercialization of cytisinicline, its drug candidate for nicotine dependence. The company says Halladay brings experience running finance at a public biopharmaceutical company, working in commercial pharmaceuticals and supporting business development. It has not established that cytisinicline will receive regulatory approval or when commercialization might occur.
Achieve CEO Andrew D. Goldberg said Halladay had helped scale a commercial pharmaceutical organization and expand its portfolio through business development within its existing capital structure. Goldberg described Halladay’s mix of public-company finance leadership and large-pharma experience as relevant to the company’s current stage.
Quick wins for a faster PC:
Scan for outdated or missing drivers - takes under a minuteDriver Scan →Clear out junk files and repair common Windows errorsFree Scan →Fix the driver behind crashes, sound loss and screen glitchesFind Drivers →Halladay said that launch discipline is built before a medicine reaches its first prescription, and that he was looking forward to building the financial and operating foundation for Achieve’s plans. His comments describe the work ahead; they do not change the candidate drug’s regulatory status.
Independent reader supportYour contribution helps us test, update, and keep practical guides available for everyone.What the appointment signals—and what it does not
The leadership change puts a finance executive with commercial-pharma and deal experience in charge of a broad finance and administrative portfolio. It is consistent with Achieve preparing its operations for a possible product launch, but the appointment itself is not evidence that cytisinicline has been approved, that a launch date is set, or that commercial success is assured.
Quick Recap
Best Value
- It can be a gift option
- Comes with secure packaging
- Helpful in various ways
Rank #4
Product prices and availability are accurate as of the date/time indicated and are subject to change. Any price and availability information displayed on Amazon at the time of purchase will apply.
